Skip to main content
Medic Debate
- The Antidote to Medical Misinformation and Propaganda!
Languages
Dansk
Nederlands
English
Français
Deutsch
Italiano
Español
Kiswahili
Svenska
Search form
Search
Main menu
Home
Search
About us
Books
Category Search
Log In
Recent posts
Treatment Protocols
You are here
Home
Gastric Cancer
Items per page
5
10
20
40
60
100
Title
Average Rating
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors.
60.00%
Update on pilot study on antitumor efficacy of intravenously applied synergistic combinations of diflunisal, PAS, and aspirin in patients with advanced solid tumors.
90.00%
The use of mushroom glucans and proteoglycans in cancer treatment.
90.00%
Psorinum, the anti cancer miracle from India.
91.47%
Psorinum therapy in treating stomach, gall bladder, pancreatic, and liver cancers: a prospective clinical study.
100.00%
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.
70.00%
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities
50.00%
Mycoplasma infections and different human carcinomas.
90.00%
Melatonin as biological response modifier in cancer patients.
80.00%
Effect of culture supernatant of Toxoplasma gondii on the proliferation and apoptosis of BGC-823 cells
70.00%
Control of cancer-associated inflammation and survival: Results from a prospective randomized phase II trial in gastric cancer.
40.00%
Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications.
70.00%
Bio-Immune therapy according to Professor Thomas Tallberg, a cure for Melanoma?
97.50%
A prospective randomised controlled study of the use of ranitidine in patients with gastric cancer. Yorkshire GI Tumour Group.
80.00%
A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gal
100.00%
To widen the setting of cancer patients who could benefit from metronomic capecitabine.
80.00%